Lindgardt Zhenya, the Chief Executive Officer of Sera Prognostics , Inc. (NASDAQ:SERA), recently sold 9,406 shares of the company’s Class A Common Stock. The transaction, which took place on May 8, 2025, was executed at a weighted average price of $2.44 per share, amounting to a total value of $22,950. The sale comes as SERA trades near its 52-week low of $2.10, with the stock down over 77% in the past year. According to InvestingPro analysis, the company maintains a strong balance sheet with more cash than debt.
The shares were sold as part of a block trade, with prices ranging from $2.10 to $2.78. This sale was mandated by the company’s policy to cover tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Zhenya holds 867,251 shares directly in the $83 million market cap company. For deeper insights into insider trading patterns and 12+ additional ProTips, check out the comprehensive SERA research report on InvestingPro.
In other recent news, Sera Prognostics reported its Q1 2025 earnings, showing a narrower-than-expected loss with an EPS of -$0.20, compared to the forecasted -$0.27. Revenue for the quarter was $38,000, falling short of the expected $200,000 but marking an improvement from zero revenue in the same quarter last year. The company remains focused on commercialization and market expansion, particularly in Medicaid and specific geographic regions. Additionally, Sera Prognostics has appointed Lee Anderson as its new Chief Commercial Officer, bringing over three decades of healthcare leadership experience to drive the commercial expansion of its products. His previous roles at Genomic Health and Exact Sciences (NASDAQ:EXAS) were marked by significant revenue growth and successful product launches. The company continues to emphasize strategic Medicaid expansion and is targeting promising pilots for managed Medicaid plans across various states. Furthermore, Sera Prognostics plans to increase its commercial presence by adding five to ten full-time employees, as part of its strategy to enhance market penetration and drive long-term growth. These developments come as the company progresses in its efforts to publish the results of its pivotal PRIME study, which may influence future market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.